Table 2.
Clinical characteristics of patients treated with continuous and intermittent infusion of intravenous vancomycin.
| Clinical characteristics | Continuous infusion (n = 11) | Intermittent infusion (n = 13) |
|---|---|---|
| Age, median [IQR] | 49 [42.5–64] | 49 [36–64] |
| Male, n (%) | 7 (63%) | 10 (76%) |
| Weight, median [IQR] | 63 [62–66] | 62 [55.8–67] |
| APACHE II, median [IQR] | 15 [14–18.5] | 17 [10–21] |
| Lungs, n (%) | 45.5 (5) | 53.8 (7) |
| Central Nervous System, n (%) | 18.2 (2) | 15.4 (2) |
| Skin or soft tissue, n (%) | 9.05 (1) | 15.4 (2) |
| Abdominal, n (%) | 18.2 (2) | 0 |
| Catheter related, n (%) | 9.02 (1) | 7.7 (1) |
| Others, n (%) | 0 | 7.7 (1) |
| Aminoglycosides concomitant therapy | 9% (1) | 23% (3) |
| Acute kidney injury after vancomycin therapya | Stage 1 – 9% (1) Stage 2 – 0% Stage 3 – 0% |
Stage 1 – 0% Stage 2 – 7.7% Stage 3 – 0% |
| Death, n (%) | 4 (36%) | 4 (31%) |
a
Evaluated by Acute Kidney Injury Network classification (AKIN).